| Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V. Patent applications |
| Patent application number | Title | Published |
|---|
| 20130125259 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a | 05-16-2013 |
| 20120258243 | METHOD AND APPARATUS FOR PRODUCING A FRESNEL ZONE PLATE - A method of producing a Fresnel zone plate ( | 10-11-2012 |
| 20120230978 | COMPOSITIONS AND METHODS FOR MODULATING CIRCADIAN SYNCHRONIZATION - The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s). | 09-13-2012 |
| 20120190580 | TREATMENT OF PATIENTS AFTER STENT IMPLANTATION OR BALLOON DILATATION AND DRUG ELUTING STENTS - The present invention relates to a nucleic acid molecule for use in the treatment or preventive treatment of a patient after stent implantation or balloon dilatation, wherein the nucleic acid molecule is selected from (a) a single-stranded nucleic acid molecule comprising or consisting of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4; (b) a hairpin RNA, wherein one of the regions forming the double-stranded portion of said hairpin RNA comprises or consists of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4; (c) an at least partially double-stranded RNA comprising two separate single strands, wherein a region within one of the strands, said region being located within the double-stranded portion of said double-stranded RNA, comprises or consists of the sequence of SEQ ID NO: 1, 2, 3 or 4 or a sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 1, 2, 3 or 4; (d) a nucleic acid molecule encoding the nucleic acid molecule of (a) or the RNA (b); and (e) a nucleic acid molecule or a two nucleic acid molecules encoding the two separate single strands of the RNA of (c). The present invention also relates to a drug eluting stent comprising the nucleic acid molecule according to the invention. | 07-26-2012 |
| 20120121579 | TREATMENT OF ONCOSTATIN M RECEPTOR BETA MEDIATED HEART FAILURE - The present invention relates to an inhibitor of the oncostatin M receptor β or an inhibitor of an activator of the oncostatin M receptor β for use in the treatment and/or prevention of heart failure. The present invention also relates to a method of treating and/or preventing heart failure comprising administering a pharmaceutically effective amount of an inhibitor of the oncostatin M receptor β or an inhibitor of an activator of the oncostatin M receptor β to a subject in need thereof. Further, the present invention also relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of heart failure. | 05-17-2012 |
| 20120094847 | THE USE OF CLASS IIB RESTRICTION ENDONUCLEASES IN 2ND GENERATION SEQUENCING APPLICATIONS - The present invention relates to a method for genotyping DNA molecules contained in at least one DNA sample comprising: (a) digesting the DNA molecules contained in at least one DNA sample with a class IIB restriction endonuclease to generate DNA fragments; (b) optionally separating DNA fragments comprising the recognition site for said class IIB restriction endonuclease from the remaining DNA fragments; (c) attaching at least one adaptor DNA to the 5′ and/or 3′ end of one or both strands of the DNA fragments comprising the recognition site for said class IIB restriction endonuclease obtained in a) or separated in b) to form adaptor-fragment constructs; (d) determining the sequence of at least a fraction of the DNA fragments obtained in c); and (e) assigning genotypes to said at least one DNA sample analysed based on the sequence data obtained in d). The present invention further relates to method for determining the position of DNA molecules comprised in a DNA library within the DNA sequence represented by said DNA library or within a known DNA sequence and for establishing a cross-reference between individual DNA molecules and their location in an at least three dimensional matrix. | 04-19-2012 |
| 20120058932 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION - The present invention relates to an active ingredient-peptide construct for extracellular concentration, a process for the concentration of active ingredients in an extracellular space of a multicellular object, the use of the active ingredient-peptide construct according to the invention for the production of a medicinal product and a pharmaceutical composition containing the active ingredient-peptide construct according to the invention. | 03-08-2012 |
| 20120046597 | ELECTRODE ARRANGEMENT FOR GENERATING A NON-THERMAL PLASMA - The invention relates to an electrode arrangement ( | 02-23-2012 |
| 20120039747 | TREATING DEVICE FOR TREATING A BODY PART OF A PATIENT WITH A NON-THERMAL PLASMA - The invention relates to a treating device ( | 02-16-2012 |
| 20120029254 | ORDERED COBALT-ALUMINUM AND IRON-ALUMINUM INTERMETALLIC COMPOUNDS AS HYDROGENATION CATALYSTS - The present invention relates to a process for the hydrogenation, in particular the selective hydrogenation of unsaturated hydrocarbon compounds, such as the selective hydrogenation of acetylene to ethylene, using a hydrogenation catalyst comprising an ordered intermetallic compound, namely an ordered cobalt-aluminum or iron-aluminum intermetallic compound. According to another aspect, the present invention relates to a catalyst comprising a support and at least one specific ordered cobalt-aluminum and/or iron-aluminum intermetallic compound supported thereon, as well as to the use of specific ordered intermetallic cobalt-aluminum and iron-aluminum intermetallic compounds as catalysts. The ordered cobalt-aluminum and iron-aluminum intermetallic compounds proved to be highly selective and long-term stable catalysts, e.g. in the selective hydrogenation of acetylene to ethylene in a large excess of ethylene. | 02-02-2012 |
| 20120009246 | PHOSPHOLIPID-ANALOGOUS COMPOUNDS - Phospholipid-analogous compounds of the general formula (I) | 01-12-2012 |
| 20110311999 | DIAGNOSTIC PREDICTION OF RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention pertains to a diagnostic assay for the diagnosis of an autoimmune disease. The present invention provides an improved diagnostic assay for the diagnosis of an autoimmune disease, particularly rheumatoid arthritis (RA) and Systemic Lupus Erythematosus (SLE). In particular the invention pertains to a method of determining in a sample of a subject the presence of two or more antibodies comprising the step of determining whether an antibody is present in a sample that specifically recognizes a hnRNP-DL polypeptide or a fragment thereof or a splice variant thereof and the further step of determining whether at least one further antibody is present in the sample that specifically recognizes a at least one other hnRNP polypeptide which is not sequence homologue to said hnRNP-DL polypeptide or fragments thereof or splice variants thereof, and/or said CCP peptide and/or a polypeptide comprising at least the Fc-part of IgG, respectively. The invention also relates to polypeptides, protein sets and antibodies that may be used in such methods and assays and for therapeutic use in RA and SLE patients. | 12-22-2011 |
| 20110293520 | NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES - The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R | 12-01-2011 |
| 20110280907 | METHOD AND SYSTEM FOR BUILDING A PHYLOGENY FROM GENETIC SEQUENCES AND USING THE SAME FOR RECOMMENDATION OF VACCINE STRAIN CANDIDATES FOR THE INFLUENZA VIRUS - A computer-implemented method and a computer system for identifying a phylogenetic tree from a plurality of biological sequences is provided. Each biological sequence is associated with a sampling date. First, the plurality of biological sequences is aligned and a distance matrix is obtained. Then, a subset of these sequences without any duplicated sequences is selected and a directed graph representation of the subset of biological sequences is generated based the associated sampling dates. Then, a minimum spanning tree is computed from the weighted directed graph representation. Then, in an iterative procedure, the sequences of unsampled evolutionary intermediates are inferred from mutation patterns that reflect the difference in sequence between the nodes in the minimum spanning tree. The new sequences are added with associated time stamps to the sequence set. Then, sets of identical sequences are removed. Then, an optimum branching is recomputed. This step is repeated until no new intermediates are found. In the final step, the sequences that have been set aside in the initializing step are added to the plurality of sequences derived in the update step. From this plurality of sequences an optimum branching is computed and identified as the phylogenetic tree. Amino acid changes repeatedly occurring on the internal branches of the obtained tree can be used to identify sequences and associated viral isolates suitable as vaccine strains for the following influenza season. | 11-17-2011 |
| 20110234219 | METHOD AND DEVICE FOR SENSING MICROWAVE MAGNETIC FIELD POLARIZATION COMPONENTS - A method for sensing a microwave magnetic field polarization component of a microwave field generated by a microwave device, comprises the steps of generating a static magnetic field having a predetermined amplitude and a predetermined direction relative to the microwave magnetic field polarization component to be sensed, preparing an atom cloud of ultracold probe atoms in defined hyperfine levels, wherein the hyperfine levels of the probe atoms are split in transition frequencies by the static magnetic field, applying a microwave pulse including the microwave magnetic field polarization component to be sensed to the atom cloud, wherein a spatial state distribution of the probe atoms is created by Rabi oscillations during the microwave pulse between the hyperfine levels of the probe atoms being resonant with the microwave magnetic field polarization component, and collecting a state image of the probe atoms, said state image depending on the spatial state distribution of the probe atoms and representing the magnetic field polarization component to be sensed. Furthermore, a sensor device being adapted for sensing a microwave field created by a microwave device is described. | 09-29-2011 |
| 20110224135 | USE OF CONKUNITZIN-S1 FOR THE MODULATION OF GLUCOSE-INDUCED INSULIN SECRETION - The present invention relates to a (poly)peptide or a peptidomimetic thereof having the biological activity of Conkunitzin-S1, wherein said (poly)peptide is selected from (a) a polypeptide comprising or having the amino acid sequence of SEQ ID NO: 1; (b) a polypeptide having at least 85% sequence identity to SEQ ID NO:1; or (c) a fragment of a) or b); wherein said (poly)peptide or peptidomimetic specifically modulates the activity of a channel having the activity of a Kv1.7 containing channel, for the treatment or prevention of metabolic diseases or conditions, or secondary diseases or conditions related to said metabolic diseases or conditions. The present invention furthermore relates to a method of screening for (poly)peptides derived from Conkunitzin-S1 suitable for specifically modulating the activity of a channel having the activity of a Kv1.7 containing channel, comprising: (a) altering the amino acid sequence of Conkunitzin-S1 represented by SEQ ID NO: 1 by deleting and/or inserting and/or replacing at least one amino acid; and (b) determining the modulatory effect of the (poly)peptide obtained in step (a) (i) on a channel having the activity of a Kv1.7 containing channel and (ii) on channels, preferably potassium channels, not having the activity of a Kv1.7 containing channel, which are optionally expressed on the same cell as the channel having the activity of a Kv1.7 containing channel. | 09-15-2011 |
| 20110191087 | COMPUTER IMPLEMENTED MODEL OF BIOLOGICAL NETWORKS - The present invention relates to a computer-implemented method of producing a kinetic model of a biological network, the method comprising (a) choosing a network topology, wherein the nodes of said topology represent biological entities and the edges of said topology represent interactions between said entities; (b) assigning kinetic laws and kinetic constants to said interactions; and (c) assigning starting concentrations to said biological entities, wherein (i) one part of said kinetic constants and independently one part of said starting concentrations are experimental data; and (ii) the remaining part of said kinetic constants and independently the remaining part of said starting concentrations are chosen randomly. | 08-04-2011 |
| 20110177973 | COMBINATORIAL SYNTHESIS AND USE OF LIBRARIES OF SHORT EXPRESSED NUCLEIC ACID SEQUENCES FOR THE ANALYSIS OF CELLULAR EVENTS - The present invention is concerned with the provision of screening assays. More specifically it relates to a method to a method for determining whether an exogenous stimulus is capable of eliciting at least one biological response in a host cell comprising the steps of (i) applying the said stimulus to a host cell which comprises a plurality of different polynucleotide constructs each construct comprising a unique expressed tag (EXT) operatively linked to an expression control sequence whose activity can be exclusively modulated by one specific signalling pathway or cellular sensor implemented in said host cell, said signalling pathway or cellular sensor being involved in eliciting a biological response and being sensitive for the exogenous stimulus, (i) determining the amount of at least one expressed tag; and (iii) comparing the amount of the at least one unique expressed tag to a suitable reference amount, whereby it is determined whether the exogenous stimulus is capable of eliciting at least one biological response in the host cell. | 07-21-2011 |
| 20110158906 | TARGETED BLOCK COPOLYMER MICELLES - The present invention provides a micelle comprising an amphiphilic block copolymer, said amphiphilic block copolymer consisting of (a) a hydrophobic polymer attached to the 5′ end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 5′ end of said second nucleic acid molecule; and/or (b) a hydrophobic polymer attached to the 3′ end of a first nucleic acid molecule, wherein said first nucleic acid molecule is hybridized with a second nucleic acid molecule, wherein a targeting unit capable of selectively binding to a specific cell type and/or tissue is attached to the 3′ end of said second nucleic acid molecule. | 06-30-2011 |
| 20110154518 | GENERATION OF INDUCED PLURIPOTENT STEM (iPS) CELLS - The present invention relates to a method of generating an induced pluripotent stem (iPS) cell comprising the step of introducing into a target cell one or two coding sequences each giving rise upon transcription to a factor that contributes to the reprogramming of said target cell into an induced pluripotent stem cell and selected from Oct3/4 or a factor belonging to the Myc, Klf and Sox families of factors, wherein the target cell endogenously expresses at least the factors that are not encoded by the coding sequences to be introduced and selected from Oct3/4 or factors belonging to the Myc, Klf and Sox families of factors, and wherein the cell resulting from the introduction of the one or two coding sequences expresses the combination of factor Oct3/4 and at least one factor of each family of factors selected from the group of Myc, Klf and Sox. Furthermore, the present invention relates to an induced pluripotent stem cell generated by the method of the invention and a method of identifying a compound that contributes to the reprogramming of a target cell into an induced pluripotent stem cell. Also, a method of generating a transgenic non-human animal and a composition comprising an iPS cell generated by the method of the present invention for gene therapy, regenerative medicine, cell therapy or drug screening are envisaged. | 06-23-2011 |
| 20110151340 | NON-AQUEOUS ELECTROLYTE CONTAINING AS A SOLVENT A BORATE ESTER AND/OR AN ALUMINATE ESTER - A non-aqueous electrolyte includes: at least one ionically conducting salt, a non-aqueous, anhydrous solvent for the ionically conductive salt, said solvent being selected to achieve a lithium transference number between 0.45 and 1.0, at least one oxide in a particulate form, said oxide being selected such that it is not soluble in said solvent and such that it is water-free. | 06-23-2011 |
| 20110129476 | MZB1, A NOVEL B CELL FACTOR, AND USES THEREOF - The marginal zone (MZ) and B1 subsets of B cells, which differ from conventional follicular (FO) B cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in MZ and B1 B cells but at low level, if at all, in FOB cells. MZB1 is involved in the regulation of proliferation, BCR-mediated signal transduction, and antibody production in B cells. Inhibitors, activators and enhancers of MZB1 expression or activity can be used as immune modulators for research and therapeutic purposes. | 06-02-2011 |
| 20110111445 | Peptide for Determining Actin Structures in Living Cells - The present invention relates to novel peptides capable of binding to action. The peptides are useful in methods for detecting actin in vitro or in living cells. | 05-12-2011 |
| 20110069755 | Method and device for image compression - A method for compressing a digital image includes selecting an image patch of the digital image; assigning the selected image patch to a specific class (z); transforming the image patch, with a pre-determined class-specific transformation function; and quantizing the transformed image patch, wherein parameters of the classifier have been learned from a set of training image patches. | 03-24-2011 |
| 20110040766 | Methods for searching with semantic similarity scores in one or more ontologies - A method assigns importance ranks to documents within repositories or databases, such as any database of documents such as books or other printed material, electronic documentation, and pages within the world-wide web. The method uses a corpus of indexed documents that has been annotated to the terms of one or more ontologies in order to assign a semantic similarity score to queries based on terms taken from the ontologies. A statistical model is used to test the significance of matches between query terms and documents or categories. The method results in an acceleration of over 10,000-fold for realistic queries and ontologies, and makes it practicable to calculate P-values dynamically or to keep database annotations and the related P-value distributions up to date by frequent recalculation. | 02-17-2011 |
| 20110027300 | Identification of a novel cysteine-rich cell penetrating peptide - The present invention relates to a nucleic acid molecule encoding a peptide capable of being internalized into a cell, wherein said nucleic acid molecule consists of (a) a nucleic acid molecule encoding a peptide having the amino acid sequence of SEQ ID NO: 2; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO: 1, wherein T is U if the nucleic acid molecule is RNA; or (d) a nucleic acid molecule encoding a peptide having at least 80% sequence identity with that of SEQ ID NO: 2, wherein at least at two positions selected from the group consisting of positions 1, 7 and 8 of SEQ ID NO: 2 a cysteine is present and wherein at least at four positions selected from the groups consisting of position 2, 4, 6, 9 or 10 of SEQ ID NO: 2 an arginine or a lysine is present. The present invention also relates to a peptide encoded by the nucleic acid of the invention, a fusion molecule comprising the peptide of the invention and a composition comprising the peptide or the fusion molecule of the invention. Furthermore, the present invention relates to a method of detecting the internalization behaviour of a fusion molecule of the invention, the composition of the invention for treating and/or preventing a condition selected from cancer, enzyme deficiency diseases, infarcts, cerebral ischemia, diabetes, inflammatory diseases, infections such as bacterial, viral or fungal infections, autoimmune diseases such as systemic lupus erythematodes (SLE) or rheumatoid arthritis, diseases with amyloid-like fibrils such as Alzheimer's disease (AD) and Parkinson's disease (PD) or certain forms of myopathy. | 02-03-2011 |
| 20110013653 | INTRA-CAVITY GENERATION OF PULSED COHERENT RADIATION IN THE UV OR XUV WAVELENGTH RANGE - A radiation source that provides high order harmonic radiation (HHG radiation) in an UV or XUV wavelength range comprising a resonant cavity that guides laser light pulses that includes at least two cavity mirrors, a first non-linear medium that provides the HHG radiation by harmonic generation based on an interaction of the laser light pulses with the first non-linear medium, wherein the first non-linear medium is arranged in the resonant cavity in an environment of reduced pressure, and a second non-linear medium arranged in the resonant cavity and adapted for at least one of amplifying the laser light pulses and phase locking longitudinal modes of the laser light pulses in the resonant cavity. | 01-20-2011 |
| 20100324293 | Monofunctionalized Perylenetetracarboxylic Acid Bismides - The invention relates to novel perylenetetracarboxylic acid bisimide derivatives with improved performance properties. | 12-23-2010 |
| 20100318187 | SURFACE-STRUCTURED POLYURETHANE SUBSTRATES AND METHODS FOR PRODUCING THE SAME - A method for producing a polymeric surface-structured substrate includes: (a) preparing a first precursor substrate that is nanostructured on at least one surface with inorganic nanoparticles, (b) coating a hardenable substrate material for a second substrate different from the first precursor substrate material onto the nanostructured surface of the precursor substrate, wherein the hardenable substrate material includes cross-linkable monomeric, oligomeric or polymeric starting components for producing a polymeric substrate, (c) hardening the hardenable substrate material to obtain a polymeric substrate, and (d) separating the precursor substrate from the polymeric substrate as a result of which a polymeric substrate nanostructured with nanoparticles and including a polyurethane is obtained. | 12-16-2010 |
| 20100310129 | IMAGE ANALYSIS METHOD, IMAGE ANALYSIS SYSTEM AND USES THEREOF - The present invention relates to an image analysis method for analyzing a digital image comprising transforming object-pixels into a vector dataset. The vector for each object pixel comprises a positional, a directional and a distance component. The number of vectors in the dataset is reduced based on neighborhood criteria. The remaining vectors can code the object by means of a centerline and pointers to its contour. | 12-09-2010 |
| 20100298518 | Silicon-Boron-Carbon-Nitrogen Ceramics and Precursor Compounds, Method for the Production and Use Thereof - The present invention relates to novel processes for preparing borylsilylamines, novel amines, novel borosilazane compounds, novel oligoborosilazane or polyborosilazane compounds which have the structural feature Si—N—B, ceramic material and methods of producing and using them. | 11-25-2010 |
| 20100280295 | USE OF A MIXTURE OF AN ORDERED INTERMETALLIC COMPOUND AND AN INERT MATERIAL AS A CATALYST AND CORRESPONDING HYDROGENATION PROCESSES - The present invention relates to a process for the hydrogenation, in particular selective hydrogenation of at least one unsaturated hydrocarbon compound comprising reacting the at least one unsaturated hydrocarbon compound with hydrogen in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst comprises a mixture of an ordered intermetallic compound and an inert material. According to another aspect, the present invention is concerned with the use of a mixture of at least one ordered intermetallic compound and at least one inert material, as a catalyst. The mixtures for use as a catalyst in the present invention can be prepared easily and achieve a superior activity in relation to the prior art, while preserving the high selectivity to the target compounds, e.g. in the selective hydrogenation of acetylene to ethylene. | 11-04-2010 |
| 20100280282 | PHOSPHATIDYL OLIGOGLYCEROLS - In order to form liposomes with a longer half-life in blood, use is made of defined compounds with the general formula (A) | 11-04-2010 |
| 20100230586 | METHOD AND APPARATUS FOR PROVIDING A SAMPLE FOR A SUBSEQUENT ANALYSIS - The invention relates to a method and an apparatus for providing a sample for a subsequent analysis of the sample, particularly for analyzing biomolecules, comprising the following steps: generating a free micro liquid jet in an environment having a predetermined pressure, wherein the micro liquid jet contains a carrier liquid and the sample to be analyzed, and dispersing the micro liquid jet into droplets containing the sample, wherein the environment surrounding the micro liquid jet is a gaseous environment in which the pressure is above vacuum conditions. | 09-16-2010 |
| 20100206745 | CORROSION INHIBITING COATING FOR ACTIVE CORROSION PROTECTION OF METAL SURFACES COMPRISING A SANDWICH-LIKE INHIBITOR COMPLEX - A corrosion inhibiting coating for active corrosion protection of a metal substrate includes, deposited on the metal substrate, a sandwich-like complex including a first inner layer of organic species, a corrosion inhibitor layer and a second outer layer of organic species, which coating is sensitive to at least one specific stimulus and releases the corrosion inhibitor in response to the stimulus. | 08-19-2010 |
| 20100188087 | SAMPLE HOLDING DEVICE, IN PARTICULAR FOR HOLDING A RODENT OR AN MR PHANTOM IN AN MRT DEVICE - A sample holding device, adapted for holding a sample, like a rodent or an MR phantom sample in a magnet bore of a magnetic resonance tomography (MRT) device, comprises a sample carrier being adapted for an arrangement in the bore of the MRT device, wherein the sample carrier comprises a carrier platform for accommodating the sample and at least one clamping part with radial locking pieces being adapted for fixing the sample carrier in a hollow enclosure structure, wherein the at least one clamping part is connected with the carrier platform. Furthermore, an MRT device and a method of MRT imaging of a sample are described. | 07-29-2010 |
| 20100187438 | Fluorescent Light Microscope For Measuring a Sample Using Red-Shifted Stokes Lines - A fluorescent light microscope for measuring a sample comprises a light source providing transfer light having a transfer wavelength for transferring a fluorescent dye in the sample from one state into another state, and a detector which measures fluorescent light from the sample with spatial resolution. The light source comprises a laser, an optical wave guide connected to the laser, and a wavelength-selective device connected to the optical wave guide. The laser emits pump light of a pump wavelength other than the transfer wavelength and injects the pump light into the optical wave guide. The pump light, due to Raman scattering being stimulated in the optical wave guide, generates a light spectrum emerging from the optical wave guide which has, besides the pump wavelength, at least one red-shifted Stokes line whose full width at half maximum is smaller than half of its distance to its next neighbor line on the blue side of the spectrum; and the wavelength-selective device singles out the transfer light by its transfer wavelength from the red-shifted Stokes lines of the light spectrum. | 07-29-2010 |
| 20100184686 | USE OF INHIBITORS FOR THE TREATMENT OF RTK-HYPERFUNCTION-INDUCED DISORDERS, PARTICULARLY CANCER - The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to over-expression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule. Finally, in addition the invention concerns a pharmaceutical composition, containing the inhibitor as described above and further a diagnostic and screening procedure. | 07-22-2010 |
| 20100176307 | STED-Fluorescent Light Microscopy with Two-Photon Excitation - A method of high spatial resolution imaging a structure in a sample comprises: marking the structure with molecules of a fluorescent dye; selecting a first wavelength for excitation light which excites the molecules of the fluorescent dye via a multi photon process for spontaneous emission of fluorescent light; focussing pulses of the excitation light into the sample to excite those molecules of the fluorescent dye present in a focal area of the focussed excitation light; selecting a second wavelength shorter than the first wavelength for de-excitation light which de-excites excited molecules of the fluorescent dye prior to their spontaneous emission; during a plurality of the pulses of the excitation light, continuously directing the de-excitation light onto the sample to de-excite excited molecules of the fluorescent dye, which are located outside an measurement area which is a fraction of the focal area; and recording the fluorescent light spontaneously emitted by the molecules of the fluorescent dye in the sample. | 07-15-2010 |
| 20100172881 | USE OF TAILORED RECOMBINASES FOR THE TREATMENT OF RETROVIRAL INFECTIONS - The present invention is directed to a method for preparing an expression vector encoding a tailored recombinase, wherein said tailored recombinase recombines asymmetric target sites within the LTR of proviral DNA of a retrovirus inserted into the genome of a host cell and is useful as means for excising the provirus from the genome of the host cell. The present invention further relates to an in vitro-method of optimising the treatment of a retroviral infection of a subject and to the use of tailored recombinases for the preparation of pharmaceutical compositions for reducing the viral load in a subjected infected by a retrovirus. | 07-08-2010 |
| 20100152051 | NOVEL METHOD FOR THE IDENTIFICATION OF CLONES CONFERRING A DESIRED BIOLOGICAL PROPERTY FROM AN EXPRESSION LIBRARY - The present invention relates to a novel method for the identification and/or characterization of clones conferring a desired biological property from an expression library. The method of the invention comprises the step of analyzing for the expression of at least one (poly)peptide, such as a tag expressed as a fusion protein, together with a recombinant insert of a clone of said expression library, wherein the clones of said expression library are arranged in arrayed form. Said (poly)peptide may be fused N-terminally or C-terminally to said insert. The method of the invention further comprises the steps of contacting a ligand specifically interacting with a (poly)peptide expressed by the insert of a clone conferring said desired biological property with a first replica of said library of clones in arrayed form and analyzing said library of clones for the occurrence of an interaction, and/or carrying out a hybridization or an oligonucleotide fingerprint with a nucleic acid probe specific for the insert of a clone conferring said desired biological property with a second replica of said library of clones arranged in arrayed form and analyzing said library of clones for the occurrence of a specific hybridization. Finally, the method of the invention requires the identification of clones wherein an expression of the at least one (poly)peptide in step (a) and/or an interaction in step (b) and/or a hybridization or an oligonucleotide fingerprint in step (c) can be detected. The present invention also relates to a kit useful for carrying out the method of the invention. | 06-17-2010 |
| 20100143991 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOLS USING AN AZOARCUS SP. EBN1 DEHYDROGENASE - A method for producing optically active alcohols of formula (Ia) or (Ib), wherein R | 06-10-2010 |
| 20100142054 | Wavelength or polarization sensitive optical assembly and use thereof - In an optical assembly having a light source which provides two optically different light components with essentially planar wavefronts on an optical axis, wherein the light components differ at least in their wavelength; in the case of an objective lens which projects the two optically different light components into a projection space; and in the case of an optical component which is arranged on the optical axis and has an plane through which the wavefronts of the two light components pass and in which at least two different areas of the optical component with different dispersion behaviors n(λ) abut against one another in the lateral direction with respect to the optical axis; the optical component causes phase shifts of the wavefronts of the two light components, wherein the phase shift of the wavefronts of the one light component differs by at least one quarter of the wavelength of that light component between the two different areas, and wherein the phase shift of the wavefronts of the other light component does not differ between the two different areas, such that an intensity distribution of the one light component in the projection space by interference with itself differs from an intensity distribution of the other light component in the projection space. | 06-10-2010 |
| 20100140506 | METHOD OF DETERMINING A MEASUREMENT VALUE ON THE BASIS OF SINGLE MOLECULE EVENTS - A method of determining a measurement value on the basis of a plurality of single molecule events of marker molecules in a sample comprises the steps of selecting the marker molecules from a group of marker molecules which are transferable between a measurable state in which a measurement signal necessary for determining the at least one measurement value is obtainable from the marker molecules and a non-measurable state, of providing the marker molecules in the sample at such an absolute concentration that the at least one measurement value is not determinable, if all marker molecules are in their measurable state, and adjusting a measurement concentration of the marker molecules in the measurable state by means of applying the physical signal to the sample at such an intensity that the at least one measurement value is determinable within a defined measurement area of the sample. | 06-10-2010 |
| 20100119780 | Body with a Surface Structure Which Enhances the Friction Behavior - Described is a body, comprising an elastomeric material or having an outer elastomeric layer, wherein a surface structure which enhances the friction behavior is formed into the surface of the elastomeric body or into the outer elastomeric layer of the body. The surface structure ( | 05-13-2010 |
| 20100069463 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF AFFECTIVE DISORDERS AND CUSHING'S SYNDROMES - The present invention relates to a method for identifying a TMEFF2 modulator, comprising (a) contacting a cell which expresses TMEFF2 with a candidate compound to be tested; (b) measuring whether said compound to be tested decreases or increases the level of a constituent of the cAMP signalling pathway, preferably the CRH signalling pathway, in said cell when compared to a corresponding cell which does not express TMEFF2; (b′) optionally determining whether said compound is capable of reduncing the binding between Activin and TMEFF2; and (c) identifying said modulator compound. Furthermore, a method for identifying a TMEFF2 modulator comprising determining whether said TMEFF2 modulator is capable of reducing the binding between Activin and TMEFF2 is contemplated. It also relates to uses and methods applying a TMEFF2 agonist for the treatment of Cushing's Syndromes and a TMEFF2 modulator for the treatment of affective disorders. Furthermore, methods of diagnosing affective disorders or Cushing's Syndromes are provided. | 03-18-2010 |
| 20100063126 | Carbazole-Derived Pharmaceutical Compositions - The present invention relates to the use of specific carbazole derivatives in the preparation of medicaments for the treatment, prevention and/or amelioration of disorders relating to pathological processes in lipid rafts. | 03-11-2010 |
| 20100048684 | EGF RECEPTOR TRANSACTIVATION BY G-PROTEIN-COUPLED RECEPTORS REQUIRES METALLOPROTEINASE CLEAVAGE OF proHB-EGF - The present invention relates to agents and methods for growth-factor receptor activation by modulating the G-protein mediated signal transduction pathway. | 02-25-2010 |
| 20100041747 | USE OF CERTAIN CHEMICAL COMPOUNDS FOR THE INHIBITION OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE ACTIVITY OF CYCLOPHILINS - The present invention relates to the use of certain spiro, ketone and carboxylic acid compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins and the use of these compounds for the production of a cosmetic or pharmaceutical composition for the promotion of hair growth or for the treatment or prevention of inflammatory autoimmune diseases, of diseases caused by fungi, of bacterial infections, of viral infections, of diseases caused by parasites, protozoa or worms, of cancer, of diseases of cells, of fibrosing diseases, and of non-neoplastic changes and diseases which are attributable to prions and changes in the structure and function of cellular proteins and cells. | 02-18-2010 |
| 20100040097 | METHOD AND DEVICE FOR CARRIER ENVELOPE PHASE STABILISATION - A method of stabilizing a carrier envelope phase of laser pulses generated with a laser device, comprising the steps of generating laser pulses with a seed laser unit, amplifying the laser pulses with an amplifier unit, generating an amplifier output signal derived from the laser pulses amplified with the amplifier unit, and controlling the carrier envelope phase of the laser pulses with an amplifier loop based on the amplifier output signal, wherein the controlling step comprises a step of adjusting an optical path of the amplifier unit in dependence on the amplifier output signal, wherein the adjusting step comprises introducing a dispersive material into the optical path of the amplifier unit. Furthermore, a stabilizing device for stabilizing a carrier envelope phase of laser pulses and a laser device including at least one stabilizing device are described. | 02-18-2010 |
| 20100022767 | DEVELOPMENT OF A SYNTHESIS OF SYRINGOLIN A AND B AND DERIVATIVES THEREOF - The synthesis of syringolin A and B and derivatives thereof as well as to pharmaceutical compositions containing the syringolin A or B or derivatives thereof and the use of syringolin A and B and derivatives thereof for prophylaxis and treatment of cancer. | 01-28-2010 |
| 20100021467 | METHOD OF DETECTING A CANCER CELL BY ABERRANT EXPRESSION OF A HUMAN K+ ION CHANNEL - The present invention relates to a novel human K | 01-28-2010 |
| 20100012897 | Luminescent Substances - The invention relates to a new class of luminescent substances (phosphorous) based on an universally dopable matrix made of an amorphous, at the most partially crystalline network of the elements P, Si, B, Al and N, preferably the composition Si | 01-21-2010 |
| 20100011461 | Nucleic acid molecules encoding enzymes having fructosyltransferase activity, and their use - Nucleic acid molecules are described which encode polypeptides having the enzymatic activity of a fructosyltransferase. Also, vectors, host cells and transgenic plants are described which contain such nucleic acid molecules. Furthermore, processes for producing polyfructose, particularly that of the inulin type, using the hosts described and/or the fructosyltransferase produced by them are described. | 01-14-2010 |
| 20090321627 | METHOD AND SYSTEM FOR HIGH THROUGHPUT MASS ANALYSIS - The invention relates to a test method, especially for mass spectroscopy of biomolecules, including the following steps: one or several samples ( | 12-31-2009 |
| 20090307790 | ISOLATION OF THE T-COMPLEX DISTORTERS AND APPLICATIONS THEREOF - The present invention relates to a method for producing a transgenic non human male animal, preferably a mammal, fish, bird or insect, wherein the transgene(s) confer(s) a change in the transmission ratio of (a) genetic trait(s) to the offspring of said non human male animal, preferably mammal, fish, bird or insect to a non-Mendelian ratio, said method comprising introducing (a) a first nucleic acid molecule encoding an expression product with a Responder function into a chromosome of a non-human germ cell, (fertilized) egg cell, embryonic cell or a cell derived therefrom, of the same species as the transgenic male to be prepared, said chromosome containing or conferring said genetic trait(s), thereby linking on said chromosome said Responder function to the genetic trait(s); and (b) at least one second nucleic acid molecule encoding an expression product with a Distorter function into (a) chromosome(s) of a non-human germ cell, (fertilized) egg cell, embryonic cell or a cell derived therefrom, of the same species as the transgenic male to be prepared, wherein said expression product with a Distorter function is a factor involved in G protein signaling, wherein said first nucleic acid molecule encoding an expression product with Responder function and said at least one second nucleic acid molecule encoding an expression product with a Distorter function are introduced into the same or different chromosomes. | 12-10-2009 |
| 20090279086 | Method and apparatus for the high spatial resolution imaging of a structure marked with a substance - For the high spatial resolution imaging of a structure in a sample ( | 11-12-2009 |
| 20090273792 | Robust three-dimensional shape acquisition method and system | 11-05-2009 |
| 20090242801 | METHOD OF FLUORESCENCE-MICROSCOPICALLY IMAGING A STRUCTURE IN A SAMPLE WITH HIGH THREE-DIMENSIONAL SPATIAL RESOLUTION - For imaging a structure in a sample with three-dimensional spatial resolution, a fluorophore is selected which is transferable by means of an optical transfer signal out of a first into a second photochromic state having specific fluorescence properties, and which displays a return rate back into the first photochromic state. The structure is labeled with the fluorophore. Via a common objective, the sample with the labeled structure is subjected both to the optical transfer signal in a spatially limited transfer-volume, and to an optical excitation signal exciting a portion of the fluorophore being in its second photochromic state for fluorescence in a spatially limited excitation-volume, the transfer-volume and the excitation-volume having a common centre of maximum intensity of the transfer signal and of the excitation signal, and a decrease of intensity of the transfer signal with the distance to the common centre of maximum intensity being substantially stronger than any decrease of the effective return rate of the fluorophore. Fluorescence light emitted by the excited fluorophore is detected. The common centre of maximum intensity is shifted with regard to the sample; and the steps of subjecting and detecting are repeated. | 10-01-2009 |
| 20090191146 | METHODS FOR THE MODULATION OF NEOVASCULARIZATION AND/OR THE GROWTH OF COLLATERAL ARTERIES AND/OR OTHER ARTERIES FROM PREEXISTING ARTERIOLAR CONNECTIONS - Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF) or a nucleic acid molecule encoding said CSF. Furthermore, the use of a CSF or a nucleic acid molecule encoding said CSF for the preparation of pharmaceutical compositions for enhancing neovascularization and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of CSFs. Described is further the use of an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through inhibition of the biological activity of CSFs for the preparation of pharmaceutical compositions for the treatment of tumors. | 07-30-2009 |
| 20090186843 | RNA sequence-specific mediators of RNA interference - The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications. | 07-23-2009 |
| 20090186773 | Methods For Predicting The Response Of Multiple Sclerosis Patients To Interferon Theraphy And Diagnosing Multiple Sclerosis - The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis (MS) patient for responsiveness to a treatment of MS by administration of interferon-α (IFN-α) and/or interferon-β (IFN-β) and means to perform the method. Furthermore, the invention relates to a method of diagnosing a predisposition of a patient for developing multiple sclerosis (MS) and corresponding means. | 07-23-2009 |
| 20090093413 | METHODS FOR THE MODULATION OF NEOVASCULARIZATION AND/OR THE GROWTH OF COLLATERAL ARTERIES AND/OR OTHER ARTERIES FROM PREEXISTING ARTERIOLAR CONNECTIONS - Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF) or a nucleic acid molecule encoding said CSF. Furthermore, the use of a CSF or a nucleic acid molecule encoding said CSF for the preparation of pharmaceutical compositions for enhancing neovascularization and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of CSFs. Described is further the use of an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through inhibition of the biological activity of CSFs for the preparation of pharmaceutical compositions for the treatment of tumors. | 04-09-2009 |
| 20090093412 | METHODS FOR THE MODULATION OF NEOVASCULARIZATION AND/OR THE GROWTH OF COLLATERAL ARTERIES AND/OR OTHER ARTERIES FROM PREEXISTING ARTERIOLAR CONNECTIONS - Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF) or a nucleic acid molecule encoding said CSF. Furthermore, the use of a CSF or a nucleic acid molecule encoding said CSF for the preparation of pharmaceutical compositions for enhancing neovascularization and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of CSFs. Described is further the use of an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through inhibition of the biological activity of CSFs for the preparation of pharmaceutical compositions for the treatment of tumors. | 04-09-2009 |
| 20090083882 | METHOD FOR INCREASING THE TOTAL OIL CONTENT IN OIL PLANTS - The invention relates to methods of increasing the total oil content and/or the glycerol 3-phosphate content in transgenic oil crop plants which comprise at least 20% by weight of oleic acid based on the total fatty acid content, preferably in plant seeds, by expressing glycerol 3-phosphate dehydrogenases (G3PDHs) from yeasts, preferably from | 03-26-2009 |
| 20090040931 | Method and device for determining the length of a shortest path in a network - A computer-implemented method for pre-processing a network, wherein the network comprises nodes and edges, each edge having a length measured according to a given metric, comprises the steps of selecting a source and a target node; determining a transit node for the selection; determining a length of a shortest path between the source node and the transit node; and storing it. A method for determining the length of a shortest path in the network may use the pre-processed network to answer the shortest path query in constant time. | 02-12-2009 |
| 20080285606 | METHOD AND APPARATUS FOR OPTICAL FREQUENCY COMB GENERATION USING A MONOLITHIC MICRO-RESONATOR - An optical frequency comb generator includes a laser device arranged for generating input laser light having a predetermined input light frequency, a dielectric micro-resonator having a cavity exhibiting a third order nonlinearity, so that the micro-resonator is capable of optical parametric generation providing parametrically generated light, and a waveguide optically coupled to the micro-resonator, the waveguide being arranged for in-coupling the input laser light into the micro-resonator and out-coupling the parametrically generated light out of the micro-resonator, wherein the laser device, the waveguide and the micro-resonator being arranged for resonantly in-coupling the laser input light to a mode of the micro-resonator with a minimum power level so that an optical field inside the cavity exceeds a predetermined cascaded parametric oscillation threshold at which the parametrically generated light includes frequencies of frequency sidebands of the input light frequency and of the sidebands thereof. | 11-20-2008 |
| 20080285041 | Optical Device for Measuring Modulated Signal Light - An optical device for determining at least one signal light component being characteristic for an optical near-field interaction of a probe with an object to be investigated, wherein the near-field interaction is subjected to a fundamental modulation at a fundamental frequency Ω, comprises an interferometer device with an illumination light path (I) being directed to the probe, a reference light path (II) being directed to a detector device for obtaining detector output signals including signal light components, and a signal light path (III) being directed from the probe to the detector device, wherein the reference and signal light paths (II, III) are superimposed at the detector device, and a demodulation device for determining the signal light components by demodulating the detector output signals, wherein the reference light path (II) does not contain the probe, an interferometer phase modulator is arranged in the reference light path (II) or signal light path (III) for changing an interferometer phase comprising the optical phase difference between the reference light and the signal light, and the demodulation device is adapted for determining the signal light components from the detector output signals obtained at three or more different interferometer states, which represent three or more different interferometer phases or at least two different interferometer phases with at least one state wherein the reference light path (II) is blocked. | 11-20-2008 |
| 20080274976 | USES OF NOVEL POTASSIUM CHANNEL BLOCKERS - The present invention is directed to kappaM (κM) conopeptide RIIIK and its use for blocking the flow of potassium ions through voltage-gated potassium channels. The κM conopeptides include unglycosylated and O-glycosylated peptides. | 11-06-2008 |
| 20080269147 | RNA interference mediating small RNA molecules - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a | 10-30-2008 |
| 20080237484 | Plasma Source - A plasma source, particularly for disinfection of wounds, comprising: an ionization chamber having an inlet for introducing a gas into the ionization chamber and further having an outlet for dispensing the ionized gas onto an object; several ionization electrodes being disposed within the ionization chamber for ionizing the gas and a predetermined ratio of the electrode-electrode distance on the one hand and the electrode-wall distance on the other hand, wherein the ratio is in a range approximately between about 1.8 and about 2.2. | 10-02-2008 |
